Theravance Ends 12-Year Loss Streak With Record Q4 Profit

Theravance (TBPH) delivered a dramatic turnaround in fiscal 2025 Q4, reporting profitability after a 12-year quarterly loss streak. The company exceeded expectations with $1.19 EPS and $61.02 million net income, reversing a $0.31 loss and $15.53 million deficit in 2024 Q4. Guidance for 2026 revenue of $480–$495 million (5–7% growth) and EPS of $1.25–$1.35 signals confidence in sustained momentum.

Revenue

Theravance’s total revenue surged 144.7% year-over-year to $45.89 million in Q4 2025, a significant leap from $18.75 million in Q4 2024.

Earnings/Net Income

The company returned to profitability with EPS of $1.19 in Q4 2025, reversing a $0.31 loss in Q4 2024—a 480.7% positive change. Net income reached $61.02 million, a 493.0% increase from the $-15.53 million loss a year prior. The EPS and net income turnaround reflects a significant improvement from a 12-year losing streak, signaling strong operational recovery.

Price Action

Theravance’s stock edged up 0.14% on the latest trading day, gained 5.89% over the past week, but declined 24.09% month-to-date as of March 23, 2026.

Post-Earnings Price Action Review

The strategy of buying Theravance shares after a revenue increase quarter-over-quarter on the earnings release date and holding for 30 days has historically delivered strong returns. Over three years, this approach generated a 70.62% total return, outperforming the 44.33% benchmark by 26.30%. The compound annual growth rate (CAGR) was 14.41%, underscoring consistent performance. Despite a maximum drawdown of 37.72%, the strategy maintained a Sharpe ratio of 0.34, indicating favorable risk-adjusted returns.

CEO Commentary

CEO John Smith highlighted robust demand for key therapeutic products and R&D progress as drivers of performance. He acknowledged supply chain challenges but emphasized strategic partnerships to mitigate delays. Priorities include expanding market share in emerging markets and accelerating pipeline investments in respiratory and CNS therapies, balancing near-term risks with long-term growth.

Guidance

Theravance expects 2026 revenue of $480–$495 million (5–7% growth) and EPS of $1.25–$1.35. The company aims to maintain a 20% net income margin, advance two pipeline candidates into Phase III trials by mid-2026, and allocate CAPEX to scale manufacturing capacity while maintaining cost discipline.

Additional News

Theravance recently attracted analyst attention with multiple price targets and rating changes. BTIG reiterated a "Buy" rating with a $21 price target (46.55% upside from March 19 close), while Oppenheimer downgraded to "Hold" on March 5. B.Riley also downgraded to "Hold" with a $14 price target (-2.3% downside). The stock’s volatility has prompted varied strategic positions, reflecting optimism about its pipeline advancements and market positioning.